Limits...
Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival.

Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Sasaguri Y - Br. J. Cancer (2011)

Bottom Line: Positive expressions of GalNAc-T6 and -T3 were immunohistochemically identified in 51% (36 of 70) and in 77% (54 of 70) of patients, respectively.The expression of GalNAc-T3 significantly correlated with good differentiation (P=0.001), but not with other clinicopathologic features.Furthermore, univariate and multivariate analyses revealed that GalNAc-T6 expression was an independent prognosis indicator for the disease, whereas GalNAc-T3 expression had no impact on clinical outcome, even though 33 of 36 GalNAc-T6-positive cases also had a positive expression of GalNAc-T3 (P=0.001, r=0.356).

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.

ABSTRACT

Background: The family of polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts) is responsible for the altered glycosylation in cancer. The purpose of our study was to investigate the clinical significance of two isoforms, GalNAc-T6 and -T3, and their correlation with the prognosis of pancreatic cancer.

Methods: Immunohistochemistry was used to analyse GalNAc-T6 and -T3 expressions in 70 clinicopathologically characterised pancreatic cancer cases.

Results: Positive expressions of GalNAc-T6 and -T3 were immunohistochemically identified in 51% (36 of 70) and in 77% (54 of 70) of patients, respectively. A close relationship was noted between GalNAc-T6 positive expression and pathological well/moderate differentiated type (P=0.001), small tumour size (P=0.044), absence of vascular invasion (P=0.009), and low stage of the American Joint Committee on Cancer systems (P=0.043). The expression of GalNAc-T3 significantly correlated with good differentiation (P=0.001), but not with other clinicopathologic features. Furthermore, univariate and multivariate analyses revealed that GalNAc-T6 expression was an independent prognosis indicator for the disease, whereas GalNAc-T3 expression had no impact on clinical outcome, even though 33 of 36 GalNAc-T6-positive cases also had a positive expression of GalNAc-T3 (P=0.001, r=0.356).

Conclusion: Both GalNAc-T6 and -T3 expressions correlated significantly with tumour differentiation, whereas only GalNAc-T6 expression predicted prognosis in pancreatic cancer.

Show MeSH

Related in: MedlinePlus

Immunofluorescent and western blotting analyses of GalNAc-T6 in pancreatic cancer cell lines PANC1 and PK1. IF, immunofluorescence. WB, western blotting. The cytoplasmic expression levels of GalNAc-T6 are significantly higher in primary cancer cell line PANC1 than those in metastatic cancer cell line PK1 with both methods.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3111199&req=5

fig4: Immunofluorescent and western blotting analyses of GalNAc-T6 in pancreatic cancer cell lines PANC1 and PK1. IF, immunofluorescence. WB, western blotting. The cytoplasmic expression levels of GalNAc-T6 are significantly higher in primary cancer cell line PANC1 than those in metastatic cancer cell line PK1 with both methods.

Mentions: The immunofluorescence staining of the pancreatic adenocarcinoma cell lines (PANC1 and PK1) showed a marked expression of GalNAc-T6 in the cytoplasm in a perinuclear manner (Figure 4). Western blotting analysis showed GalNAc-T6 expression in the cytoplasm, whereas very weak nuclear expression was detectable in both cell lines (Figure 4). Additionally, the expression levels of GlaNAc-T6 in PANC1 were significantly higher than those in the PK1 cell line by both methods.


Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival.

Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Sasaguri Y - Br. J. Cancer (2011)

Immunofluorescent and western blotting analyses of GalNAc-T6 in pancreatic cancer cell lines PANC1 and PK1. IF, immunofluorescence. WB, western blotting. The cytoplasmic expression levels of GalNAc-T6 are significantly higher in primary cancer cell line PANC1 than those in metastatic cancer cell line PK1 with both methods.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3111199&req=5

fig4: Immunofluorescent and western blotting analyses of GalNAc-T6 in pancreatic cancer cell lines PANC1 and PK1. IF, immunofluorescence. WB, western blotting. The cytoplasmic expression levels of GalNAc-T6 are significantly higher in primary cancer cell line PANC1 than those in metastatic cancer cell line PK1 with both methods.
Mentions: The immunofluorescence staining of the pancreatic adenocarcinoma cell lines (PANC1 and PK1) showed a marked expression of GalNAc-T6 in the cytoplasm in a perinuclear manner (Figure 4). Western blotting analysis showed GalNAc-T6 expression in the cytoplasm, whereas very weak nuclear expression was detectable in both cell lines (Figure 4). Additionally, the expression levels of GlaNAc-T6 in PANC1 were significantly higher than those in the PK1 cell line by both methods.

Bottom Line: Positive expressions of GalNAc-T6 and -T3 were immunohistochemically identified in 51% (36 of 70) and in 77% (54 of 70) of patients, respectively.The expression of GalNAc-T3 significantly correlated with good differentiation (P=0.001), but not with other clinicopathologic features.Furthermore, univariate and multivariate analyses revealed that GalNAc-T6 expression was an independent prognosis indicator for the disease, whereas GalNAc-T3 expression had no impact on clinical outcome, even though 33 of 36 GalNAc-T6-positive cases also had a positive expression of GalNAc-T3 (P=0.001, r=0.356).

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.

ABSTRACT

Background: The family of polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts) is responsible for the altered glycosylation in cancer. The purpose of our study was to investigate the clinical significance of two isoforms, GalNAc-T6 and -T3, and their correlation with the prognosis of pancreatic cancer.

Methods: Immunohistochemistry was used to analyse GalNAc-T6 and -T3 expressions in 70 clinicopathologically characterised pancreatic cancer cases.

Results: Positive expressions of GalNAc-T6 and -T3 were immunohistochemically identified in 51% (36 of 70) and in 77% (54 of 70) of patients, respectively. A close relationship was noted between GalNAc-T6 positive expression and pathological well/moderate differentiated type (P=0.001), small tumour size (P=0.044), absence of vascular invasion (P=0.009), and low stage of the American Joint Committee on Cancer systems (P=0.043). The expression of GalNAc-T3 significantly correlated with good differentiation (P=0.001), but not with other clinicopathologic features. Furthermore, univariate and multivariate analyses revealed that GalNAc-T6 expression was an independent prognosis indicator for the disease, whereas GalNAc-T3 expression had no impact on clinical outcome, even though 33 of 36 GalNAc-T6-positive cases also had a positive expression of GalNAc-T3 (P=0.001, r=0.356).

Conclusion: Both GalNAc-T6 and -T3 expressions correlated significantly with tumour differentiation, whereas only GalNAc-T6 expression predicted prognosis in pancreatic cancer.

Show MeSH
Related in: MedlinePlus